source
- GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent lossGSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion. The company says the savings will be redirecte…
- Alnylam shares tumble 30% even as biotech sector ralliesAlnylam's stock fell about 30% on July 28, 2026, even though the broader biotech market is experiencing a resurgence. The market rebound follows years of a bearish environment, with increased merg…